Esperion Therapeutics (ESPR) PT Lowered to $12 at Needham & Company, Keeps 'Buy' as Financing Extends Runway Into 2023
Tweet Send to a Friend
Needham & Company analyst Chad Messer lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $12.00 (from $20.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
